S9704-S0014-S0313A Studying Genes in Samples From Patients With Limited or Advanced Diffuse Large B-Cell Lymphoma
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. It may also help doctors find better ways to treat cancer.
PURPOSE: This research trial studies genes in samples from patients with limited and advanced diffuse large B-cell lymphoma.
Genetic: RNA analysis
Genetic: gene expression analysis
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
|Study Design:||Time Perspective: Retrospective|
|Official Title:||Determining the Cell of Origin and Prognostic Gene Signatures in SWOG Trials of Diffuse Large B-Cell Lymphoma|
- Proportion of GCB phenotype among limited-stage vs advanced-stage patients [ Time Frame: Retrospectively ] [ Designated as safety issue: No ]
- Differences in PFS between limited- and advanced-stage patients with the GCB and non-GCB phenotypes [ Time Frame: Retrospectively ] [ Designated as safety issue: No ]
- Association between GCB markers and OS [ Time Frame: Retrospectively ] [ Designated as safety issue: No ]
|Study Start Date:||February 2012|
|Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|
- To determine the proportion of the cell of origin subtypes (germinal center B-cell-like [GCB] vs non-GCB) and expression levels of prognostic genes previously identified in diffuse large B-cell lymphoma (DLBCL) in patient biopsy samples from SWOG trials of limited- and advanced-stage DLBCL, and to assess the association between the results and progression-free survival (PFS).
- To assess the association between these marker results and overall survival (OS).
OUTLINE: Archived formalin-fixed paraffin-embedded tissue are analyzed for gene expression profile by quantitative nuclease protection assay (qNPA) and immunohistochemical analyses. Results are then compared with each patient's progression-free survival and overall survival.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01563861
|Principal Investigator:||Daniel O. Persky, MD||University of Arizona|